0001609410-16-000004.txt : 20160902 0001609410-16-000004.hdr.sgml : 20160902 20160902113906 ACCESSION NUMBER: 0001609410-16-000004 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20160902 DATE AS OF CHANGE: 20160902 EFFECTIVENESS DATE: 20160902 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEMISPHERX BIOPHARMA INC CENTRAL INDEX KEY: 0000946644 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 520845822 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-270035 FILM NUMBER: 161867622 BUSINESS ADDRESS: STREET 1: 1617 JFK BLVD, SUITE #500 STREET 2: ONE PENN CENTER CITY: PHILADELPHIA STATE: PA ZIP: 19103 BUSINESS PHONE: 215-988-0080 MAIL ADDRESS: STREET 1: 1617 JFK BLVD, SUITE #500 STREET 2: ONE PENN CENTER CITY: PHILADELPHIA STATE: PA ZIP: 19103 D 1 primary_doc.xml X0707 D LIVE 0000946644 HEMISPHERX BIOPHARMA INC 1617 JFK BLVD, SUITE #500 ONE PENN CENTER PHILADELPHIA PA PENNSYLVANIA 19103 215-988-0080 DELAWARE None None Corporation true Thomas K Equels 1617 JFK Blvd Philadelphia PA PENNSYLVANIA 19103 Executive Officer Director Adam Pascale 1617 JFK Blvd Philadelphia PA PENNSYLVANIA 19103 Executive Officer David Strayer 1617 JFK Blvd Philadelphia PA PENNSYLVANIA 19103 Executive Officer Wayne Springate 1617 JFK Blvd Philadelphia PA PENNSYLVANIA 19103 Executive Officer William Mitchell 1617 JFK Blvd Philadelphia PA PENNSYLVANIA 19103 Director Peter W Rodino 1617 JFK Blvd Philadelphia PA PENNSYLVANIA 19103 Director Stewart Appelrouth 1617 JFK Blvd Philadelphia PA PENNSYLVANIA 19103 Director Pharmaceuticals Decline to Disclose 06b false 2016-08-30 false true false 6600 H.C. Wainwright & Co., LLC 375 None None 430 Park Avenue New York NY NEW YORK 10022 CA CALIFORNIA IL ILLINOIS NJ NEW JERSEY NY NEW YORK TX TEXAS false 33334 33334 0 Warrants herein sold to investors when investors purchased registered shares. $01 of the total $1.50 per share purchase price of securities allocated to purchase of private warrants referred to herein. false 3 2333 true 0 represents same percentage of total commissions received for combination of public share and private warrant offering as set forth in item 13 above. 0 true false HEMISPHERX BIOPHARMA INC Thomas K. Equels Thomas K. Equels President 2016-09-01